Coherus Oncology, Inc. (CHRS)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net revenue | 10,254 | 7,599 | 70,774 | 64,979 |
| Selling, general and administrative | 26,039 | 26,025 | 34,744 | 35,165 |
| Research and development | 26,306 | 24,356 | 21,676 | 21,955 |
| Cost of goods sold | 3,395 | 2,653 | 20,741 | 28,368 |
| Total costs and expenses | 55,740 | 53,034 | 77,161 | 85,488 |
| Loss from operations | -45,486 | -45,435 | -6,387 | -20,509 |
| Interest expense | 2,277 | 2,150 | 5,362 | 5,334 |
| Other income (expense), net | 2,901 | 187 | 2,084 | 1,467 |
| Gain (loss) on sale of interest in projects | - | - | -1,086 | 24,085 |
| Gain (loss) on extinguishment of debt | - | - | - | -12,630 |
| Loss from continuing operations before income taxes | -44,862 | -47,398 | -10,751 | -12,921 |
| Net loss from continuing operations | -44,862 | -47,398 | - | - |
| Net income from discontinued operations, net of tax (note 6) | 342,629 | -9,171 | - | - |
| Net income (loss) | 297,767 | -56,569 | -10,751 | -12,921 |
| Earnings per share, basic | 2.57 | -0.49 | -0.09 | -0.11 |
| Earnings per share, diluted | 2.57 | -0.49 | -0.09 | -0.11 |
| Weighted average number of shares outstanding, basic | 116,077,710 | 115,857,780 | 115,210,091 | 114,819,965 |
| Weighted average number of shares outstanding, diluted | 116,077,710 | 115,857,780 | 115,210,091 | 114,819,965 |